Inhalable liposome sustained release composition for use in the treatment of lung disease

摘要

Provides a liposome sustained release composition for use in the treatment of lung disease.The liposome sustained release comprises liposomes that contain polyethylene glycol (PEG) - modified lipids and encapsulate tyrosine kinase inhibitors.Tyrosine kinase inhibitors are stably encapsulated in liposomes and obtained liposome drug formulations can be aerosolized or sprayed to administer through inhalation.This aerosolized liposome formulation provides consistent pharmacokinetic and pharmacodynamic profiles while achieving the desired efficacy and safety.No selection